Semaglutide (Wegovy)
Indication
Managing overweight and obesity (NICE TA875)
NICE TA 875 - Semaglutide for managing overweight and obesity
Brand:
Wegovy
Nice TA:
875
Commissioning responsibility:
CCG
PbR excluded:
No
Background
1.1 Semaglutide is recommended as an option for weight management, including weight loss and weight maintenance, alongside a reducedcalorie diet and increased physical activity in adults, only if:
• it is used for a maximum of 2 years, and within a specialist weight management service providing multidisciplinary management of overweight or obesity (including but not limited to tiers 3 and 4), and
• they have at least 1 weight-related comorbidity and:
－ a body mass index (BMI) of at least 35.0 kg/m2 , or
－ a BMI of 30.0 kg/m2 to 34.9 kg/m2 and meet the criteria for referral to specialist weight management services in NICE's guideline on obesity: identification, assessment and management.
Use lower BMI thresholds (usually reduced by 2.5 kg/m2 ) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.